Breadcrumb Home Studies Studies Search Filter Research Area AllComplications & ComorbiditiesCureTreatmentTuberculosis Study Status AllClosed to AccrualClosed to Follow UpConcludedEnrollingIn DevelopmentOpen to AccrualParticipants Off Study and Primary Analysis CompletedPendingTemporarily Closed (Paused) to Accrual and Study Agents/ProductsWithdrawn Sort Study Number AscStudy Number Desc Submit Search Showing 23 studies. IMPAACT 2032: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States DAIDS Number 38746 Research Area Treatment Study Status Pending Locality United States IMPAACT 2029: Phase I/II Study of Switching to Fixed Dose Combination Dolutegravir/Rilpivirine among Virologically Suppressed Children and Adolescents Living with HIV DAIDS Number TBD Research Area Treatment Study Status In Development Locality US & Non-US IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum DAIDS Number 38609 Research Area Treatment Study Status Pending Locality US & Non-US IMPAACT 2023: A Phase I Study of the Safety and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Treatment Study Status In Development Locality US & Non-US IMPAACT 2022: Phase II Study of the Virologic Efficacy and Feasibility of Long-Acting Injectable Antiretroviral Medications in Non-Adherent Youth with HIV DAIDS Number 38631 Research Area Treatment Study Status In Development Locality United States IMPAACT 2019: Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of Age DAIDS Number 38504 Research Area Treatment Study Status Enrolling Locality US & Non-US IMPAACT 2017: MOCHA DAIDS Number 30070 Research Area Treatment Study Status Enrolling Locality US & Non-US IMPAACT 2014: Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-infected Children and Adolescents DAIDS Number 34150 Research Area Treatment Study Status Closed to Accrual Locality US & Non-US IMPAACT 2010: VESTED DAIDS Number 30129 Research Area Treatment Study Status Closed to Follow Up Locality US & Non-US IMPAACT 2007: Phase I Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Neonates at Risk of Acquiring HIV-1 Infection DAIDS Number 20734 Research Area Treatment Study Status Participants Off Study and Primary Analysis Completed Locality US & Non-US Pagination Current page 1 Page 2 Page 3 Next page Next
IMPAACT 2032: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States DAIDS Number 38746 Research Area Treatment Study Status Pending Locality United States
IMPAACT 2029: Phase I/II Study of Switching to Fixed Dose Combination Dolutegravir/Rilpivirine among Virologically Suppressed Children and Adolescents Living with HIV DAIDS Number TBD Research Area Treatment Study Status In Development Locality US & Non-US
IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum DAIDS Number 38609 Research Area Treatment Study Status Pending Locality US & Non-US
IMPAACT 2023: A Phase I Study of the Safety and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Treatment Study Status In Development Locality US & Non-US
IMPAACT 2022: Phase II Study of the Virologic Efficacy and Feasibility of Long-Acting Injectable Antiretroviral Medications in Non-Adherent Youth with HIV DAIDS Number 38631 Research Area Treatment Study Status In Development Locality United States
IMPAACT 2019: Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of Age DAIDS Number 38504 Research Area Treatment Study Status Enrolling Locality US & Non-US
IMPAACT 2017: MOCHA DAIDS Number 30070 Research Area Treatment Study Status Enrolling Locality US & Non-US
IMPAACT 2014: Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-infected Children and Adolescents DAIDS Number 34150 Research Area Treatment Study Status Closed to Accrual Locality US & Non-US
IMPAACT 2010: VESTED DAIDS Number 30129 Research Area Treatment Study Status Closed to Follow Up Locality US & Non-US
IMPAACT 2007: Phase I Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Neonates at Risk of Acquiring HIV-1 Infection DAIDS Number 20734 Research Area Treatment Study Status Participants Off Study and Primary Analysis Completed Locality US & Non-US
